From PCOS to PMOS: What the Name Change Means for Your Fertility Practice
If you have been in clinical practice for any length of time, you have probably had the conversation. A new client sits down and tells you she has been diagnosed with polycystic ovary syndrome. She has had an ultrasound. She may or may not actually have polycystic ovaries. Her GP may have focused entirely on her cycle irregularity. Nobody has mentioned insulin resistance, androgen excess, metabolic risk, or the fact that her cardiovascular and mental health picture is as clinically relevant as her cycle.
This week, that conversation changed. After hearing from 22,000 people over 11 years, polycystic ovary syndrome has been officially renamed polyendocrine metabolic ovarian syndrome, or PMOS, introduced in a paper published in The Lancet and presented at the European Congress of Endocrinology.
For those of us working in fertility nutrition, this is not a minor administrative update. It is a formal scientific endorsement of the way advanced practitioners have been understanding and approaching this condition for years. And it has significant practical implications for how you communicate with clients, how you build your protocols, and how you position your clinical expertise.
Why The old name was always the wrong name
The old name implied that people with PMOS have many abnormal cysts on their ovaries. When the condition was first described in the 1930s, doctors physically examined patients' ovaries during operations and noticed they looked lumpy and bumpy. But a true abnormal cyst has a particular type of lining that these follicles do not have. I did a recent session with Amrita Nutrition on fertility and the first one on PCOS and fertility which already looks out of date now! But the principle is still the same and the initial information centred around the frustration on the name and how it didn't reflect what was happening inside the body.
The damage done by that original misnaming has been significant and measurable. For decades, the term polycystic ovary syndrome has been widely recognised as inaccurate and limiting. This mischaracterisation has had tangible consequences: delayed diagnoses, fragmented care, stigma, and missed opportunities for early intervention in metabolic and cardiovascular risks.
Many of your clients will have arrived at your door already carrying the wrong mental model of their own condition. They think of it as an ovarian problem, or a gynaecological problem. Something that means their ovaries look wrong on a scan. They may have been told they just need to lose weight. They may have been put on the pill and sent home. What they almost certainly have not been told is that their condition is a complex, multisystem condition involving endocrine, metabolic, reproductive, dermatological and psychological health. That is the gap you are trained to fill. And the new name makes that gap, and your role in addressing it, explicitly visible.
What PMOS actually tells us
The new name, polyendocrine metabolic ovarian syndrome, was chosen through iterative global surveys with responses from 14,360 people with PCOS and multidisciplinary health professionals from all world regions, using modified Delphi methods and nominal group technique workshops, with principles prioritising scientific accuracy, clarity, stigma avoidance, and cultural appropriateness.
Break the name down and it is a clinical map of how you should be approaching every PMOS client:
Polyendocrine tells you this is a multi-gland, multi-hormone condition. You are not just looking at ovarian androgens. You are looking at the HPA axis, the HPO axis, thyroid function, adrenal output, insulin signalling. Every endocrine system is potentially involved and needs to be assessed.
Metabolic tells you that insulin resistance, blood sugar dysregulation, lipid patterns, and cardiovascular risk are core features, not secondary complications. This is where your functional testing skills and dietary intervention have the most to offer and where standard gynaecological care most consistently falls short.
Ovarian retains the reproductive focus, acknowledging that follicular development, ovulation, and hormonal cyclicity remain central to the clinical picture, especially for your fertility clients.
Syndrome acknowledges that this is a heterogeneous condition. No two PMOS presentations are identical. This is a clinical truth that every experienced practitioner already knows but that the old name obscured.
What this means practically for your fertility clients?
-
Your clients will start seeing PMOS in the press, on social media, and eventually in letters from their GP. Some will be confused. Some will feel like their diagnosis has been taken away. Some will feel genuinely relieved that a name finally describes what they experience.
Your role is to be the practitioner who can explain this clearly, confidently, and in a way that is clinically useful rather than confusing. Reframe it as good news: the science has finally caught up with the reality of what this condition is. The name changing does not change their diagnosis. It changes how that diagnosis is understood and that change is entirely in their favour.
-
The PMOS framework gives you a clinically justified reason to assess systems that some clients (and some practitioners) have previously considered outside the scope of a fertility appointment. Insulin resistance is not a side issue. It is a core feature. Thyroid function is not optional to assess. It is integral. Adrenal patterns, HPA axis dysregulation, cortisol, sleep, and stress are not soft add-ons. They are polyendocrine components of the condition.
When you explain this to clients using the new name and its meaning, you are not overstepping. You are doing exactly what the international scientific consensus now formally recognises as appropriate.
-
The metabolic component of PMOS is where nutritional therapy has the strongest evidence base and the greatest clinical leverage. Blood sugar stability is the foundation of every PMOS fertility protocol. Inositol, berberine, ALA, chromium, magnesium. The insulin-sensitising toolkit is well-evidenced and directly relevant to the newly named condition.
For your fertility clients specifically, the metabolic picture matters for more than just ovulation. A more pathophysiologically meaningful nomenclature leads to improved diagnostic clarity, better patient communication, and more precise clinical management. Elevated insulin suppresses SHBG, raises free androgens, disrupts the LH:FSH ratio, and impairs follicular development. Correcting the metabolic picture is not just a weight management strategy. It is a direct fertility intervention.
-
One of the most significant clinical implications of the new name is the formal recognition of the polyendocrine nature of the condition. For your fertility clients, this means thyroid assessment is now even more explicitly non-negotiable. The relationship between subclinical hypothyroidism and PMOS is bidirectional. Thyroid underfunction worsens insulin resistance and androgen excess, and PMOS-driven metabolic dysfunction impairs T4 to T3 conversion. A TSH within the NHS normal range is not sufficient reassurance in a PMOS fertility case. Aim for 1.0 to 2.0 mIU/L. Assess FT3, FT4, and both antibody markers.
-
Stakeholders highlighted that the current name does not adequately reflect broad PCOS features and is confusing, and endorsed a name change, with perceived advantages outweighing potential disadvantages. One of those advantages is reducing stigma and stigma has been a genuine clinical problem. Clients with PMOS have often internalised a narrative that their condition is primarily about weight, appearance, and failing to have regular periods. The new name, properly explained, opens the door to a more complete and compassionate conversation about what is actually happening in their body.
In your fertility consultations, this matters because chronic psychological stress and the emotional weight of a misunderstood diagnosis both activate the HPA axis and suppress the HPO axis. Helping a client understand their diagnosis more accurately is not just good communication. It is part of the clinical intervention.
A note on terminology in practice
In the immediate term, you will need to use both names. Your clients will still be searching for PCOS. Their GPs will still be writing PCOS on referral letters. The NHS and international disease classification systems will take time to update. Updates to clinical guidelines, medical education and international disease classification systems are now underway to ensure the new terminology is adopted consistently worldwide.
The practical approach is to introduce PMOS as the new name, explain what it means and why it was changed, and use both terms in your written materials and client communications for the transition period. For your Academy blog and practitioner content, however, lead with PMOS. Your audience of trained practitioners should be ahead of the curve, not following it.
The bigger picture for your practice
This name change is a formal, Lancet-published, globally endorsed recognition that PMOS is a multisystem endocrine and metabolic condition, which is precisely the clinical territory where nutritional therapy and functional medicine operate with the most depth and evidence.
The GP who diagnoses PMOS will, in most cases, offer metformin and the pill. They will not have the time or training to assess thyroid antibody trajectories, design a phase-specific supplement protocol, interpret a Mira cycle alongside a DUTCH test, or address the relationship between insulin signalling and follicular development in the granulosa cells.
You do. And if you feel this might be a little overwhelming this is exactly what we do inside the Fertility Academy my 10 month programme designed to get you to this level in no time! If you are already in – browse to detail on the prospectus and get in touch!
This post was written for qualified nutritional therapists and functional medicine practitioners training with the AH Fertility Academy. For more on working with PMOS in clinical practice, see the Academy modules on insulin resistance, thyroid function in fertility, and advanced functional testing.
References: The Lancet, May 2026. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process.